首页> 外文期刊>Nature biotechnology >Optogenetics for in vivo cardiac pacing and resynchronization therapies
【24h】

Optogenetics for in vivo cardiac pacing and resynchronization therapies

机译:用于体内心脏起搏和再同步治疗的光遗传学

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abnormalities in the specialized cardiac conduction system may result in slow heart rate or mechanical dyssynchrony. Here we apply optogenetics, widely used to modulate neuronal excitability(1-4), for cardiac pacing and resynchronization. We used adeno-associated virus (AAV) 9 to express the Channelrhodopsin-2 (ChR2) transgene at one or more ventricular sites in rats. This allowed optogenetic pacing of the hearts at different beating frequencies with blue-light illumination both in vivo and in isolated perfused hearts. Optical mapping confirmed that the source of the new pacemaker activity was the site of ChR2 transgene delivery. Notably, diffuse illumination of hearts where the ChR2 transgene was delivered to several ventricular sites resulted in electrical synchronization and significant shortening of ventricular activation times. These findings highlight the unique potential of optogenetics for cardiac pacing and resynchronization therapies.
机译:专门的心脏传导系统异常可能导致心律缓慢或机械不同步。在这里,我们应用光遗传学,广泛用于调节神经元兴奋性(1-4),用于心脏起搏和再同步。我们使用腺相关病毒(AAV)9在大鼠的一个或多个心室部位表达Channelrhodopsin-2(ChR2)转基因。这允许在体内和孤立的灌注心脏中以蓝光照明以不同的跳动频率对心脏进行光遗传学起搏。光学作图确认新起搏器活性的来源是ChR2转基因的传递位置。值得注意的是,ChR2转基因被递送到多个心室部位的心脏的漫射照明导致电同步并显着缩短了心室激活时间。这些发现凸显了光遗传学在心脏起搏和再同步治疗中的独特潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号